Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2012, vol. 21, nr 5, September-October, p. 581–589

Publication type: original article

Language: English

Cross-Protection Among Unrelated Leptospira Pathogens Serovars: An Unfinished Story

Odporność krzyżowa u niepowiązanych serotypów Leptospira – niedokończona opowieść

Luis A. Rosario1,A,B,C,D,E,F, Daniel F. Arencibia2,A,B,C,D,E,F, Yolanda E. Suarez3,C,E,F, Juan F. Infante2,C,E,F, Bárbara Y. Valdés2,B,C, Niurka Batista2,A,B,C,D,E,F

1 Institute of Pharmacy and Food Science, University of Havana, Havana, Cuba

2 Finlay Institute, Havana, Cuba

3 Veterinary Medicine Faculty, Agrarian University of Havana (UNAH), Mayabeque, Cuba

Abstract

Background. The World Health Organization considers leptospirosis the most neglected zoonotic disease in the last decades. One of the major obstacles in the developing of vaccines for the prevention of leptospirosis is the absence of cross-protection among unrelated serovars. It is accepted that cross-protection among related serovars is due to antibodies generated against lipopolysaccharides (LPs), whereas a cross-protection among unrelated serovars is rarely observed.
Objectives. The objective of the study was to ascertain the existence of cross-protection among vaccine strains of different serovars.
Results. The results of this research demonstrated that a cross-protection among unrelated Leptospira serovars strain is possible. The Canicola strain is able to induce protection against homologous, Ballum and Copenhageni strains. The Mozdok strain induced protection only against a homologous challenge. Other strains showed a moderate cross-protection against a heterologous challenge.
Conclusion. These findings suggest that the Canicola and Mozdok strains are ideal candidates for developing a new vaccine formulation for use in Cuba.

Streszczenie

Wprowadzenie. Światowa Organizacja Zdrowia uważa leptospirozę za najbardziej lekceważoną chorobę odzwierzęcą w ostatnich dziesięcioleciach. Jedną z głównych przeszkód w rozwoju szczepionek zapobiegających leptospirozie jest brak odporności krzyżowej wśród niepowiązanych serotypów. Przyjmuje się, że odporność krzyżowa wśród powiązanych serotypów wynika z przeciwciał wytworzonych przeciwko lipopolisacharydom (LPs), a wśród niepowiązanych serotypów odporność krzyżowa występuje rzadko.
Cel pracy. Ustalenie, czy odporność krzyżowa występuje między szczepionkami opartymi na szczepach różnych serotypów.
Wyniki. Badania wykazały, że odporność krzyżowa wśród niepowiązanych szczepów serotypów Leptospira jest możliwa. Szczep L. canicola jest w stanie wywołać odporność przed szczepami homologicznymi, Ballum i Copenhageni. Szczep L. mozdok wywołał odporność tylko przed homologicznym szczepem. Inne szczepy wykazały umiarkowaną odporność krzyżową przed heterologicznym wyzwaniem.
Wnioski. Wyniki badań sugerują, że szczepy L. canicola i L. mozdok są idealnymi kandydatami na składnik nowej szczepionki do użytku na Kubie.

Key words

Leptospira, leptospirosis, cross-protection, vaccine, Mesocricetus auratus

Słowa kluczowe

Leptospira, leptospiroza, odporność krzyżowa, szczepionka, Mesocricetus auratus

References (30)

  1. Vinetz JM: Leptospirosis. Curr Opin Infect Dis 2001, 14, 527–538.
  2. Trueba G, Zapata S, Madrid K, Cullen P, Haake D: Cell aggregation: a mechanism of pathogenic Leptospira to survive in fresh water. Int Microbiol 2004, 7, 35–40.
  3. Waitkins SA: Leptospirosis as an occupational disease. Br J Ind Med 1986, 43, 721–725.
  4. McBride AJ, Athanazio DA, Reis MG, Ko AI: Leptospirosis. Curr Opin Infect Dis 2005, 18, 376–386.
  5. Adler B, de la Peńa M: Leptospira and Leptospirosis. Vet Microbiol 2009, 2, 4382–4392.
  6. Faine S, Adler B, Bolin C, Perolat P: Leptospira and leptospirosis. Medisci Melbourne 1999, 135–165.
  7. Kuriakose M, Eapen CK, Paul R: Leptospirosis in Kolenchery, Kerala, India: epidemiology, prevalent local serogroups and serovars and a new serovar. Eur J Epidemiol 1997, 13, 691–697.
  8. Gravekamp C, Van De Kemp H, Franzen M, Carrington D, Schoone GJ, Van Eys GJJM: Detection of seven species of pathogenic leptospiras by PCR using two sets of primers. J Gen Microbiol 1993, 139, 1691–1700.
  9. Faine S: Leptospira and leptospirosis, CRC Press, Boca Raton [FL], 1994.
  10. Jost BH, Adler B, Vinh T, Faine S: A monoclonal antibody reacting with a determinant on leptospiral lipopolysaccharide protects guinea pigs against leptospirosis. J Med Microbiol 1986, 22, 269–275.
  11. Levett PN: Leptospirosis. Clin Microbiol Rev 2001, 14, 296–326.
  12. Cinco M, Domenis R, Perticarari S, Presani G, Marangoni A, Blasi E: Interaction of leptospiras with murine microglial cells. New Microbiol 2006, 29(3), 193–199.
  13. Sonrier C, Branger C, Michel V, Ruvoen-Clouet N, Ganiere JP, Andre-Fontaine G: Evidence of cross-protection within Leptospira interrogans in an experimental model. Vaccine 2001, 19(1), 86–94.
  14. Silva EF, Medieros MA, Mc Bride AJA, Matasunga J, Esteves GS, Ramos JGR: The terminal portion of leptospiral immunoglobulin-like protein Lig A confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 2007, 25(33), 6277–6286.
  15. Silva E, Santo C, Athanazio D, Seyffert N, Seixas F, Cerqueira GM: Characterization of virulent Leptospira isolates in hamster model. Vaccine 2008, 26, 3892–3896.
  16. Reed LJ, Muench H: A simple method of estimation fifty percent end-points. Am J Hyg 1938, 27, (3), 493–497.
  17. Finlay Institute: Sanitary Registration of vax-SPIRAL (trivalent antileptospirosic vaccine), 1998, 23–25.
  18. González A, Rodríguez Y, Batista N, Valdés Y, Núńez JF, González M: Booster effect of an active immunization with Leptospira interrogans serogroup Ballum in hamsters vaccinated with vax-SPIRAL. VacciMonitor 2003, 12(2), 1–6.
  19. KIT Biomedical Research. International Course on Laboratory Methods for the Diagnosis of Leptospirosis. Amsterdam: Royal Tropical Institute; 2006.
  20. Falkow S: Molecular Koch’s postulates applied to microbial pathogenicity. Rev Infect Dis 1988, 10(2), 274–276.
  21. Hem A, Smith AJ, Solberg P: Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret, and mink. Lab Animal 1998; 32, (4), 364–368.
  22. Cole JR, Sulzer CR, Pursell AR: Improved microtechnique for the leptospiral microscopic agglutination test. Appl Microbiol 1973, 25, 979–980.
  23. Oliva R, Infante J, González M, González I, Farińas M: Clinical and pathological characterization of leptospirosis in Golden Syrian hamster and Duncan Hartley guinea pig by means of experimental infection with three L. interrogans serovars. VacciMonitor 1998, 7(5), 8–13.
  24. Matsunaga J, Young T, Barnett J, Barnett D, Bolin C, Haake D: Novel 45-kilodalton leptospiral protein that is processed to a 31-kilodalton growth-phase-regulated peripheral membrane protein. Infect Immun 2002, 70(1), 323–334.
  25. Barnett J, Barnett D, Bolin C, Summers T, Wagar E, Cheville N: Expression and distribution of leptospiral outer membrane components during renal infection of hamsters. Infect Immun 1999, 67, 853–861.
  26. Merien F, Truccolo J, Baranton G, Perolat P: Identification of a 36-kDa fibronectin-binding protein expressed by a virulent variant of Leptospira interrogans serovar Icterohaemorrhagiae. FEMS Microbiol Lett 2000, 185, 17–22.
  27. Merien F, Baranton G, Perolat P: Invasion of Vero cells and induction of apoptosis in macrophages by pathogenic Leptospira interrogans are correlated with virulence. Infect Immun 1997, 65(2), 729–738.
  28. Suepaul SM, Carringtonb CV, Campbell M, Bordea G, Adesiyuna AA: Study on the efficacy of Leptospira vaccines developed from serovars isolated from Trinidad and comparison with commercial vaccines using a hamster model. Vaccine 2010, 28 (1), 5421–5426.
  29. Chapman A, Everard COR, Faine S, Adler B: Antigens recognized by the human immune response to severe leptospirosis in Barbados. Epidemiol Infect 1991, 107, 143–155.
  30. Biswas D, Roy S, Vijayachari P, Sugunan A, Nararajaseenivasan K, Sehgal S: Comparison of immunoreactive proteins of commonly circulating serogroups of Leptospira in Andaman Islands. India J Med Res 2005, 121, 151–158.